Healthcare professionals' perspectives towards the digitalisation of paediatric growth hormone therapies: expert panels in Italy and Korea.

To analyse the perspectives of healthcare professionals (HCPs) regarding the acceptance of digital health solutions for growth hormone (GH) deficiency care. This study identified factors impacting HCPs' intent to use and recommend digital solutions supporting recombinant-human growth hormone (r-hGH) therapy in Italy and Korea with a use case of connected drug delivery system (Aluetta Participatory workshops were conducted in Rome, Italy, and Seoul, Korea, to collect the perspectives of 22 HCPs on various predefined topics. HCPs were divided into two teams, each moderated by a facilitator. The workshops progressed in five phases: introduction of the project and experts, capturing views on the current context of digitalisation, perceived usefulness and ease of use of Aluetta HCPs from both Italy and Korea perceived Aluetta HCPs' perspectives on the digitalisation in paediatric GH therapies suggested that digital solutions enable automatic, real-time injection data transmission to support adherence monitoring and evidence-based therapy, strengthen HCP-patient relationships, and empower patients throughout the GH treatment process.

Informations de copyright

Copyright © 2024 Rivera Romero, Chae, Faienza, Vergani, Cheon, Di Mase, Frasca, Lee, Giavoli, Kim, Klain, Moon, Iezzi, Yeh, Aversa, Rhie and Koledova.

Déclaration de conflit d'intérêts

All attendees (HCPs) received a fee for participation. EV received fee as consultant from Merck Serono Italy. ORR has participated in an advisory board for Merck. EK is an employee of Merck Healthcare KGaA, Darmstadt, Germany, and holds shares in the company. JY is an employee of Merck Ltd., Seoul, South Korea, an affiliate of Merck KGaA, Darmstadt, Germany. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.